Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial CancerInternational Journal of Gynecological Cancer - Tập 27 Số 4 - Trang 738-742 - 2017
Ji Young Hwang, Da Hee Kim, Hyo Sook Bae, Mi‐La Kim, Yong Wook Jung, Bo Seong Yun, Seok Ju Seong, Eunah Shin, Mi Kyoung Kim
ObjectiveThe aim of this study was to evaluate the oncologic and pregnancy outcomes of combined oral medroxyprogesterone acetate (MPA)/levonorgestrel-intrauterine system (LNG-IUS) treatment in young women with grade 2–differentiated stage IA endometrial adenocarcinoma who wish to preserve fertility.Methods... hiện toàn bộ
First-Line Therapy in Ovarian Cancer TrialsInternational Journal of Gynecological Cancer - Tập 21 Số 4 - Trang 756-762 - 2011
Tate Thigpen, Andreas duBois, Jessica N. McAlpine, Philip J. DiSaia, Keiichi Fujiwara, William J. Hoskins, Gunnar B. Kristensen, Robert S. Mannel, Maurie Markman, Jacobus Pfisterer, Michael Quinn, Nick Reed, Ann Marie Swart, Jonathan S. Berek, Nicoletta Colombo, Gilles Freyer, Dolores Gallardo, Marie Plante, Andrés Poveda, Larry Rubinstein, Monica Bacon, Henry C Kitchener, Gavin Stuart
At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 di...... hiện toàn bộ
Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian CancerInternational Journal of Gynecological Cancer - Tập 21 Số 4 - Trang 763-770 - 2011
Jonathan A. Ledermann, Christian Marth, Mark S. Carey, Michael J. Birrer, David D.L. Bowtell, Stan B. Kaye, Iain A. McNeish, Amit M. Oza, Giovanni Scambia, Gordon Rustin, Frederick B. Stehman, David M. Gershenson, Gillian Thomas, Els M.J.J. Berns, Antonio Casado, Nelleke Ottevanger, Felix Hilpert, Byoung‐Gie Kim, Aikou Okamoto, Monica Bacon, Henry C Kitchener, Gavin Stuart
There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of ...... hiện toàn bộ